GlassScriptPhysician profile
Jennifer C Liquido
NPI 1316903842
$2,058.54
in general payments reported to CMS, 2019-2025
31 companies · $258 in 2025
The $258 reported for 2025 was more than what 81% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $279 · 2021: $511 · 2022: $232 · 2023: $204 · 2024: $171 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $348.86 | 2019-2025 | Vaxneuvance, Vaxelis, Rotateq |
| Novo Nordisk INC | $194.45 | 2019-2025 | Wegovy |
| Abbott Laboratories | $182.10 | 2021-2025 | Freestyle Libre 3, Eterna |
| Insulet Corporation | $171.33 | 2020-2025 | Omnipod |
| Tris Pharma INC | $152.82 | 2019-2023 | Dyanavel Xr |
| Lilly USA, LLC | $146.40 | 2019-2021 | |
| Lifescan, INC. | $83.37 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $80.91 | 2019-2024 | |
| Glaxosmithkline, LLC. | $76.30 | 2019-2025 | Pediarix, Penmenvy, Bexsero |
| Amneal Pharmaceuticals LLC | $68.91 | 2023 | Unithroid |
| Shire North American Group INC | $57.56 | 2019 | |
| Becton, Dickinson and Company | $56.48 | 2020-2022 | |
| Amarin Pharma, INC. | $44.30 | 2020-2021 | |
| Pfizer INC. | $40.23 | 2022-2023 | |
| Cequr Corporation | $35.77 | 2024-2025 | Cequr Simplicity |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $34.89 | 2019 | |
| Dexcom, INC. | $34.25 | 2021 | |
| Corcept Therapeutics | $31.53 | 2019-2023 | Korlym |
| Sanofi US Services INC. | $27.78 | 2025 | |
| Adlon Therapeutics L.P. | $21.89 | 2020 | |
| Medtronic, INC. | $19.70 | 2022 | |
| Valeritas, INC. | $19.14 | 2019 | |
| Seqirus USA INC | $18.87 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.27 | 2025 | Zoryve |
| Ultragenyx Pharmaceutical INC. | $15.44 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.72 | 2019 | |
| Sequel Med Tech, LLC | $14.43 | 2025 | Twiist |
| Ibsa Pharma INC. | $12.55 | 2020 | |
| Ironshore Pharmaceuticals INC. | $12.38 | 2019 | |
| Sobi, INC | $12.07 | 2022 | |
| Mannkind Corporation | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Liquido listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.